By Jennifer Ahlstrom | Posted - Oct 19th, 2017





Clinical Trial: New Inhibitor Targeting Cancer Progression Pathway for Myeloma and Lymphoma

Enzymes which control cell cycle progression, DNA replication and pathway signaling can impact one key pathway called NF-κB (NF kappa B). This pathway is known to trigger the progression of multiple myeloma. In laboratory studies, a new drug called TAS4464 showed it could stop myeloma cells from growing and kill myeloma cells. It is intended as an addition to today's myeloma treatment arsenal of options. 

The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma. The Phase 2 portion of the study will investigate the efficacy and safety of TAS4464 in patients with multiple myeloma or lymphoma.

There are 6 active sites for this trial in the following states: Maryland, Massachusetts, Michigan, Minnesota, New York and Ohio.

Learn more and connect with this trial directly at: 

TAS4464 Clinical Trial To find eligible clinical trials for your myeloma, click here:  Find All Myeloma Clinical Trials

Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .